Brief: Spyre Therapeutics Announces Launch Of Spy772 Program
10/08/2026 14:50
BRIEF-Spyre Therapeutics Announces Launch Of Spy772 Program Aug 10 (Reuters) - Spyre Therapeutics Inc SYRE.O:
SPYRE THERAPEUTICS ANNOUNCES LAUNCH OF SPY772 PROGRAM AND INITIATION OF PHASE 2 SKYLIGHT TRIAL IN HIDRADENITIS SUPPURATIVA
Source text: ID:nGNXc3dzRL
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock